BryoLogyx is developing a new class of drugs to enhance the response rates and treatment durability
of cancer immunotherapies and anti-HIV agents. The company’s initial focus is on cancer, where it is capitalizing on two recent scientific
advances: the discovery that a complex natural product, bryostatin, stimulates tumor antigen production to amplify the immune response unleashed by
cancer immunotherapy; and the invention of the first practical synthetic production method for bryostatin and analogs, enabling their
availability for commercial development. BryoLogyx has exclusive rights from Stanford University to the method’s use in the areas of
cancer and HIV. Bryostatin, currently in development for use with immuno-oncology agents, has an established
safety profile based on clinical studies involving more than 1100 patients.